GeneCode Ltd was founded in 1993 in Tallinn, Estonia. GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing innovative treatment strategies in neurodegenerative diseases and anti-virals. For neurodegenerative diseases, GeneCode applies proprietary drug design technologies for innovative target mechanisms. This enables the synthesis and development of novel small-molecule drug candidates which validates the target biology towards its proposed indications, such as Parkinson`s disease, spinal cord injury, Huntington`s disease, motor neuronal disease, multiple sclerosis, Alzheimer`s disease and pain. The overall ambition is to develope neuroprotective and potentially neurorestorative treatment which is –as yet- unavailable.
With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. By disrupting the viral lifecycle GeneCode`s approach is delivering promising treatment options for Hepatitis C, HIV and Chikungunya virus.
All proprietary methods for novel drug design technologies and drug candidates developed by GeneCode are aimed to function as disease modifyers and ultimately as cures, not as disease symptom treatments. Both the identification and optimization of small molecule methods towards growth factor receptors and the antisense technologies have been globally patented and serve GeneCode`s new Technological Platforms of drug design.
Partners and shareholders
GENECODE scientific partners are all internationally well known leading scientists in various areas of biomedical sciencies. GENECODE scientific partners have published more then 600 publications with more then 30 000 citations and are inventors or coinventors of more than 50 patent families and patents.
Prof. Mart Saarma
Dr. Mehis Pilv
Thomas Bjoern Waldin
Prof. Tõnis Timmusk
Prof. Andres Merits
Dr. Yulia Sidorova
Dr. Eric Ronken
Platform technology patents
US Patent No.: US 8,901, 129 B2, Date of Patent Dec.2, 2014, European Patent No EP2509953, March 30, 2016
“METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS”
US Patent no., US 7,786, 292 B2, Date of Patent Aug. 31, 2010, European Patent No EP2013044, Aug. 29, 2012
“ANTISENSE AGENTS COMBINING STRONGLY BOUNDING BASE-MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE”